Global Ibuprofen Market By Type (USP and EP), By Application (Tablet, Capsule, and Suspension), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global Ibuprofen Market By Type (USP and EP), By Application (Tablet, Capsule, and Suspension), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)
Trusted Business Insights has published a comprehensive market research report on, Global Ibuprofen Market by Type (USP and EP), By Form Type (Table, Capsule, and suspension), By Sales Channel (Retail, Online, Hypermarket & drug store) and by Region -Global Forecast to 2030, which offers a holistic view of the global Ibuprofen market through systematic segmentation that covers every aspect of the target market.

The global ibuprofen market is projected to be US$ 7223.0 Mn in 2020 to reach US$ 9140.2 Mn by 2030 at a CAGR of 2.4%.

Ibuprofen is a drug in the nonsteroidal anti-inflammatory drug (NSAID) category belonging to a group of propionic acid derivatives. It is commonly used for the treatment of pain, fever, and inflammation. It is indicated for analgesic and anti-inflammatory effect in the treatment of rheumatoid arthritis (including juvenile rheumatoid arthritis or Stills disease), osteoarthritis, ankylosing spondylitis and other non-rheumatoid (seronegative) arthropathies. In the treatment of non-articular rheumatic conditions, ibuprofen is indicated in particular conditions such as frozen shoulder (capsulitis), bursitis, tendonitis, tenosynovitis and low-back pain. It can also be used in soft-tissue injuries such as sprains and strains. It is also indicated for its analgesic effect in the relief of mild to moderate pain such as dysmenorrhea, dental and post-operative pain.

Global ibuprofen market is expected to register steady growth over the forecast period. Increasing cardiovascular diseases, cancer, arthritis, and other chronic diseases is one of the significant factors fueling the growth of the target market. Also, the growing population, coupled with a heavy burden of the ageing population is an additional factor expected to support the growth of the target market. Easy availability and its extensive distribution network of such NSAID category drugs are further expected to augment the growth of the global ibuprofen market.


Global Ibuprofen Market Revenue (US$ Mn), 2021 to 2030


Ibuprofen is an effective antipyretic and analgesic in children and is considered safe when administered to children and even in infants younger than six months. It is useful to treat mild fever, dental pain, gastrointestinal pain, etc. for a short duration. It is also useful to close a patent ductus arteriosus in premature babies. Growing younger population and adoption of ibuprofen as a safe drug for the treatment of mild symptoms is also expected to boost the growth of the target market further.

Furthermore, presence of a high number of pharmaceutical companies providing ibuprofen in various forms such as tablets, powder, capsules, liquid, etc. in a range of dosages for various age groups is another expected to augment the growth of the market. Also, the drug is not under a patent, and several generic versions are available at a very economical price.
However, adverse effects of ibuprofen such as nausea, dyspepsia, diarrhea, constipation, headache, dizziness, rash, salt and fluid retention, along with other severe side effects including heart failure, high blood levels of potassium, kidney impairment, aggravating asthma, and others, is a major factor hamper growth of the target market to a certain extent.

Availability of OTC drugs including Ibuprofen on online portals has been gaining significant traction for the past couple of years. The emergence of pharmacy portals such as drugs.com, dokteronline.com, mCHEMIST.com, Medidart.com, etc. and availability of prescription and non-prescription drugs on these websites, is a trend likely to continue and provide a substantial boost to the global ibuprofen market


Global Ibuprofen Market by Type, 2018


On the basis of type, the market is segmented into USP, EP. USP accounts for the majority share in the global Ibuprofen market.

On the basis of region, the market is segmented into North America, Europe, APAC, South America and MEA. North America accounts majority share in the global Ibuprofen market.
The research report on the global Ibuprofen market includes profiles of some of the major companies such as Shandong Xinhua Pharmaceutical Co., Ltd., IOL Chemicals and Pharmaceuticals Limited, Hubei Biocause Pharmaceutical Co., Ltd, Strides Pharma Science Limited (Shasun Pharmaceuticals Limited), BASF SE, SI Group, Inc. Perrigo Company plc, Mallinckrodt plc, and other prominent players.



Below are the active patents related to Ibuprofen Market.


Patent Number: US20090186883A1

Stable Aqueous Suspension

Abstract

An aqueous pharmaceutical suspension comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) an aqueous buffer system; (iii) xanthan gum; (iv) polyvinyl pyrrolidone; and (v) glycerol wherein the suspension is free from pregelatinised starch, amino polycarboxylic acid, microcrystalline cellulose, hydroxypropylmethyl cellulose, polyoxyethylene sorbitan monooleate, silicon dioxide and taste modifying agents selected from the group consisting of bulk sweeteners, intense sweeteners, flavouring agents and mixtures thereof.

Application File Date: 2007-05-10

Application Granted Date: 2016-07-26

Current Assignee: Norbrook Laboratories Ltd 

Key Market Segments:

By Type

  
USP
  
EP

By Application

  
Tablet
  
Capsule
  
Suspension
  
Others

By End-User

  
CROs and CMOs
  
Pharmaceutical and Biopharmaceutical Company


Key Market Players included in the report:


  
Al Nabeel International Ltd.
  
Alveda Pharmaceuticals Inc.
  
Amnel
  
BASF SE
  
BIOCAUSE Inc.
  
CSL Limited
  
Cumberland Pharmaceuticals Inc.
  
Germin MED
  
Grifols S.A.
  
Harbin Gloria Pharmaceuticals Co.Ltd.
  
Hubei Biocause Pharmaceutical Co.Ltd
  
IOL Chemicals And Pharmaceuticals Limited
  
Laboratorios Valmorca C.A.
  
Mallinckrodt plc
  
Perrigo Company plc
  
Pfizer
  
PT. Soho Industri Pharmasi
  
Sandor Medicaids Pvt. Ltd.
  
Shandong Xinhua Pharmaceutical Co.Ltd.
  
SI Group, Inc.
  
Solara Active Pharma Sciences Limited
  
Strides Pharma Science Limited (Shasun Pharmaceuticals Limited)
  
Xinhua Pharmaceutical etc.


Below are the key development related to Ibuprofen Market in 2020 and 2021.


July 2021: Hyloris Announces Launch of Maxigesic® IV, a Novel Non-Opioid Pain Treatment, in Key European Markets. Marks first European launches of Maxigesic IV, a well-tolerated and effective non-opioid pain treatment. Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that Maxigesic IV is now available in Germany, the largest European pharmaceutical market, and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion. Hyloris’ partner AFT Pharmaceuticals works together with distribution partners with strong local presence to commercialise the product globally. Maxigesic IV is currently licensed in more than 100 countries across the globe, and it has been registered in 24 countries. Following the launch in Germany and Austria, the product is now available in 5 countries: Australia, New Zealand, The United Arab Emirates, Germany, and Austria. Source

March 2021: Combogesic® - First Acetaminophen + Ibuprofen Combination Tablet - Now Available for Canadians with Acute Pain. New treatment option offers a clinically proven 3.3:1 acetaminophen to ibuprofen ratio. BioSyent Inc. ("BioSyent", "the Company"), (TSXV: RX) is pleased to announce Combogesic® is now available in many pharmacies across Canada. Combogesic® is indicated for the short-term management of mild to moderate acute pain and the reduction of fever in adults over 18 years. Combogesic® is the first Health Canada approved combination analgesic that provides the double action of two well-known and effective medicines, acetaminophen and ibuprofen, in one - patented formulation - tablet. Source

February 2021: Strides gets USFDA nod for Ibuprofen OTC oral suspension. Strides is focusing on building a private label business in the US by leveraging its portfolio of products across soft gels, tablets, capsules, topicals, powders and oral solutions. Strides Pharma Science Limited has announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte Limited, Singapore, has received approval for Ibuprofen Oral Suspension USP, 100 mg/5 mL (OTC) from the United States Food & Drug Administration (USFDA). Source

March 2020: FDA approves combination ibuprofen-acetaminophen drug for U.S. ADA has long-advocated for over-the-counter combination drug. The Food and Drug Administration has approved the first over-the-counter ibuprofen and acetaminophen combination drug for the U.S.The product — called Advil Dual Action — will be available nationwide later in 2020 and contains 250 mg of ibuprofen and 500 mg of acetaminophen. Source